Aranesp Declines Put More Pressure On Amgen For Denosumab Success
With sales of Amgen's blockbuster anemia franchise in a freefall and competitive threats to its tumor necrosis factor inhibitor Enbrel looming, the big biotech is banking on the osteoporosis treatment denosumab to drive growth in the years ahead
You may also be interested in...
Pfizer set to become Amgen’s partner on Enbrel in North America.
Novel RANK ligand inhibitor could have Oct. 19, 2009, PDUFA date.
If denosumab is approved, Amgen may need to provide physicians with a shield against the financial risk of stocking the injectable osteoporosis treatment in their offices